<DOC>
	<DOC>NCT02667444</DOC>
	<brief_summary>This is a 12 week, multi-center, double-blinded, randomized, vehicle-controlled, parallel group, study to be conducted in approximately 1300 subjects with acne vulgaris in the US.</brief_summary>
	<brief_title>P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne</brief_title>
	<detailed_description>This is a double-blind, placebo controlled study in subjects with moderate to severe acne. Subjects who satisfy the entry criteria will be randomized to SB204 4% QD or Vehicle Gel QD in a 1:1 ratio. Efficacy assessments will include Investigator Global Assessments (IGA) and inflammatory and non-inflammatory lesion counts. Subjects will return for post-Baseline evaluation at Weeks 2, 4, 8, and 12/Early Termination (ET).</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Moderate to severe acne Minimum of 25 and no more than 70 noninflammatory lesions (open and closed comedones) on the face Minimum of 20 and no more than 40 inflammatory lesions (papules and pustules) Women of childbearing potential who are pregnant, nursing, considering becoming pregnant Any dermatologic condition that could interfere with clinical evaluations including severe, recalcitrant cystic acne</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>